Non-motor signs and symptoms in Parkinson’s disease


Motor symptoms are cardinal clinical features of Parkinson’s disease (PD). Progress in drug therapy and rehabilitation has been presenting beneficial effect for motor symptoms. However, non-motor symptoms and signs in PD have been accumulated growing attentions and its amelioration may also give beneficial effect for PD patients’ and their care givers’ quality of life. In this mini-review, I overviewed non-motor symptoms and signs in PD.

Share and Cite:

Abe, K. (2012) Non-motor signs and symptoms in Parkinson’s disease. Health, 4, 1133-1137. doi: 10.4236/health.2012.431171.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] Parkinson, J. (2002) An essay on the shaking palsy. The Journal of Neuropsychiatry and Clinical Neurosciences, 14, 223-236. doi:10.1176/appi.neuropsych.14.2.223
[2] Hoehn, M.M. and Yahr, M.D. (1967) Parkinsonism, onset, progression and mortality. Neurology, 17, 427-442. doi:10.1212/WNL.17.5.427
[3] Jankovic, J. (2008) Parkinson’s disease, clinical features and diagnosis. Journal of Neurology, Neurosurgery & Psychiatry, 79, 368-376. doi:10.1136/jnnp.2007.131045
[4] Duvoisin, R.C. and Sage, J. (2001) Parkinson’s disease. A guide for patient and family. 5th Edition, Lippincott Williams & Wilkins, Philadelphia, New York.
[5] Abe, K. (2002) Frontier in treatment. Parkinson disease— Role of rehabilitation. Brain Medicine, 14, 45-54.
[6] Coelho, M. and Ferreira, J.J. (2012) Late-stage Parkinson disease. Nature Reviews Neurology, 8, 435-442.
[7] Schenkman, M., Hall, D.A., Baron, A.E., Schwartz, R.S., Mettler, P. and Kohrt, W.M. (2012) Exercise for people in early-or midstage Parkinson disease, a 16-month randomized controlled trial. Physical Therapy, 92, 1395-1410. doi:10.2522/ptj.20110472
[8] Gr?ber, S., Liepelt-Scarfone, I., Brüssel, T., Schweitzer, K., Gasser, T. and Berg, D. (2011) Self estimated quality of life in monogenetic Parkinson’s disease. Movement Disorders, 26, 187-188. doi:10.1002/mds.23209
[9] Chaudhuri, K.R., Healy, D.G. and Schapira, A.H.V. (2009) Non-motor symptoms of Parkinson’s disease, diagnosis and management. Lancet Neurology, 8, 464-474. doi:10.1016/S1474-4422(09)70068-7
[10] Abe, K., Takanashi, M. and Yanagihara, T. (2000) Fatigue in patients with Parkin-son’s disease. Behavioural Neurology, 12, 103-106.
[11] Martinez-Martin, P., Schapira, A.H.V. and Stocchi, F. (2007) Prevalence of nonmotor symptoms in Park-inson's disease in an international setting study using nonmotor symptoms questionnaire in 545 patients. Movement Disorders, 22, 1623-1629. doi:10.1002/mds.21586
[12] Chaudhuri, K.R., Martinez-Martin, P., Brown, R.G., Sethi, K., Stocchi, F., Odin, P., Ondo, W., Abe, K., MacPhee, G., MacMahon, D., Barone, P., Rabey, M., Bonnuccelli, U., Forbes, A., Breen, K., Tluk, S., Naidu, Y., Olanow, C.W., Thomas, S., Rye, D., Bowron, A., Williams, A.J. and Schapira, A.H.V. (2007) The metric proper-ties of a novel non-motor symptoms scale for Parkinson’s disease, results from an international pilot study. Movement Disor- ders, 22, 1901-1911. doi:10.1002/mds.21596
[13] Zanigni, S., Calandra-Buonaura, G., Grimaldi, D. and Cortelli, P. (2011) REM behaviour disorder and neurode-generative diseases. Sleep Medicine, 12, S54-S58. doi:10.1016/j.sleep.2011.10.012
[14] Martinez-Martin, P., Rodriguez-Blazquez, C., Abe, K., Bhattacharyya, K.B., Bloem, B.R., Carod-Artal, J., Dill, B., Esselink, R., Falup-Pecurariu, C., Gallardo, M,. Mir, P., Naidu, Y., Nicoletti, A,. Sethi, K., Tsuboi, Y., van Hilten, J.J., Visser, M., Zappia, M. and Chaudhuri, K.R. (2009) International validation of the non-motor symptoms scale, comparison with the pilot study. Neurology, 73, 1584-1591. doi:10.1212/WNL.0b013e3181c0d416
[15] Martinez-Martin, P., Rodriguez-Blazquez, C., BKurtis, M.M., Chaudhuri, K.R. and The NMSS Validation Group (2011) The impact of non motor symptoms on health-re- lated quality of life of patients with Parkinson’s Disease. Movement Disorders, 26, 399-406. doi:10.1002/mds.23462
[16] Hoehn, M.M. and Yahr, M.D. (1967) Parkinsonism, onset, progression and mortality. Neurology, 17, 427-442. doi:10.1212/WNL.17.5.427
[17] Fénelon, G., Mahieux, F. and Huon, R. (2000) Hallucinations in Parkinson’s Disease. Prevelance, phenomenology and risk factors. Brain, 123, 733-745. doi:10.1093/brain/123.4.733
[18] Jenner, J. and Laar van, T. (2012) Visual hallucinations in Parkinson’s disease. In: Stone, J.H. and Blouin, M., Eds., International Encyclopedia of Reha-bilitation.
[19] Cummings, J.L. and Masterman, D.L. (1999) Depression in patients with Parkinson’s disease. International Jour- nal of Geriatric Psychiatry, 14, 711-718. doi:10.1002/(SICI)1099-1166(199909)14:9<711::AID-GPS4>3.0.CO;2-1
[20] Remy, P., Doder, M. and Lees, A. (2005) Depression in Parkinson’s disease. Loss of dopamine and nora-drenaline innervations in the limbic system. Brain, 128, 1314-1322. doi:10.1093/brain/awh445
[21] Rektorova, I., Rektor, I. and Bares, M. (2003) Pramipex- ole and pergolide in the treatment of depression in Parkinson’s disease, a national multicentre prospective randomized study. European Journal of Neurology, 10, 399- 406. doi:10.1046/j.1468-1331.2003.00612.x
[22] Barone, P., Scarzella, L. and Marconi, R. (2006) Pramipex- ole versus ser-traline in the treatment of depression in Parkinson’s disease. A national multicenter parallel group randomized study. Journal of Neurology, 253, 601-607. doi:10.1007/s00415-006-0067-5
[23] Lemke, M.R., Brecht, H.M. and Koester, J. (2005) Anhedonia, depression and motor functioning in Parkinson’s disease during treatment with pramipexole. The Journal of Neuropsychiatry and Clinical Neurosciences, 17, 214- 220. doi:10.1176/appi.neuropsych.17.2.214
[24] Czernecki, V., Pillon, B. and Houeto, J.L. (2002) Motiva- tion, reward and Parkinson’s disease, influence of dopa therapy. Neuropsychologia, 40, 2257-2267. doi:10.1016/S0028-3932(02)00108-2
[25] Aarsland, D., An-dersen, K., Larsen, J.P., Lolk, A. and Kragh-S?rensen, P. (2003) Prevalence and characteristics of dementia in Parkinson disease. Archives of Neurology, 60, 387-392. doi:10.1001/archneur.60.3.387
[26] Williams-Gray, C.H., Foltynie, T. and Brayne, C.E.G. (2007) Evolution of cognitive dysfunction in an incident Parkinson’s disease cohort. Brain, 130, 1787-1798. doi:10.1093/brain/awm111
[27] Cooper, J.A., Sagar, H.J. and Jordan, N. (1991) Cognitive impairment in early, untreated Parkinson’s disease and its relationship to motor disability. Brain, 114, 2095-2122. doi:10.1093/brain/114.5.2095
[28] Fujiwara, M., Yamauchi, K. and Abe, K. (2007) Rehabilitation in Parkinson disease. Monthly Book Medical Rehabilitation, 76, 44-52.
[29] Chaudhuri, K.R., Pal, S. and DiMarco, A. (2002) The Parkinson’s disease sleep scale, a new instrument for assessing sleep and nocturnal disability in Parkinson’s disease. Journal of Neurology, Neurosurgery & Psychiatry, 73, 629-635. doi:10.1136/jnnp.73.6.629
[30] Homann, C.N., Wenzel, K., Suppan, K., Ivanic, G., Kriech- baum, N., Crevenna, R. and Ott, E. (2002) Sleep attacks in patients taking dopamine agonists, review. BMJ, 324, 1483-1487. doi:10.1136/bmj.324.7352.1483
[31] Diagnostic Classification Steering Committee (1990) International classification of sleep disorders, diagnostic and coding manual. American Sleep Disorders Association, Rochester.
[32] Abe, K., Hikita, T. and Sakoda, S. (2005) Sleep disturbances in Japanese patients with Parkinson’s disease-Comparing with patients in the UK. Journal of Neurol Science, 234, 73-78. doi:10.1016/j.jns.2005.03.036
[33] Abe, K., Hikita, T. and Sakoda, S. (2005) Zolpidem tartrate therapy for sleep disturb-ances in patients with Parkinson’s disease. Journal of the Neurological Sciences, 238, S350. doi:10.1016/S0022-510X(05)81350-4
[34] Goetz, C.G., Ouyang, B., Negron, A. and Stebbins, G.T. (2010) Hallucinations and sleep disorders in PD, ten-year prospective longitudinal study. Neurology, 75, 1773-1779. doi:10.1212/WNL.0b013e3181fd6158
[35] Abe, K. (2008) Zolpidem therapy for movement disorders. Recent Patents on CNS Drug Discovery, 3, 55-60. doi:10.2174/157488908783421519
[36] Medow, M.S., Stewart, J.M., Sanyal, S., Mumtaz, A., Sica, D. and Frishman, W.H. (2008) Pathophysiology, diagnosis, and treatment of orthostatic hypotension and vasova- gal syncope. Cardiology in Review, 16, 4-20.
[37] Fitzmaurice, H., Fowler, C.J, Rickards, D., Kirby, R.S., Quinn, N.P., Marsden, C.D., Milroy, E.J. and Turner- Warwick, R.T. (1985) Micturition disturbance in Parkinson’s disease. British Journal of Urology, 57, 652-656. doi:10.1111/j.1464-410X.1985.tb07025.x
[38] Duncan, R.P., Leddy, A.L., Cavanaugh, J.T., Dibble, L.E., Ellis, T.D., Ford, M.P., Foreman, K.B. and Earhart, G.M. (2012) Accuracy of fall prediction in Parkinson disease, six-month and 12-month pro-spective analyses. Parkinson’s Disease, 237673.
[39] Clarke, C.E., Zobkiw, R.M. and Gullaksen, E. (1995) Quality of life and care in Parkinson’s disease. British Journal of Clinical Practice, 49, 288-293.
[40] Kamata, N. and Abe, K. (2008) Accidental falls and overestimation of stability limits in Parkinsonian patients. In: Murray, C.A., Ed., Accidental Falls, Causes, Prevention, and Interventions, Nova Science Publishers and Inc., New York, 200-243.
[41] Jain, S. and Goldstein, D.S. (2012) Cardiovascular dysautonomia in Parkinson disease, from pathophysiology to pathogenesis. Neurobiology of Disease, 46, 572-580. doi:10.1016/j.nbd.2011.10.025
[42] Singharam, C., Ashraf, W. and Gaummitz, E.A. (1995) Dopaminergic defect of enteric nervous system in Park- inson’s disease patients with chronic constipation. Lancet, 346, 861-864. doi:10.1016/S0140-6736(95)92707-7
[43] Abbott, R.D., Petrovitch, H. and White, L.R. (2001) Frequency of bowel movements and the future risk of Parkinson’s disease. Neurology, 57, 456-462. doi:10.1212/WNL.57.3.456
[44] Braak, H., Del Tredici, K., Rüb, U., de Vos, R.A., Jansen-Steur, E.N. and Braak, E. (2003) Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiology of Aging, 24, 197-211. doi:10.1016/S0197-4580(02)00065-9
[45] Clark, E.C., Mulder, D.W., Erickson, D.J., Clements, B.G. and Maccaty, C.S. (1957) Parkinson’s disease, therapeutic exercises in its management. Postgraduate Medicine, 21, 301-308.
[46] Kalf, J.G., de Swart, B.J., Borm, G.F., Bloem, B.R. and Munneke, M. (2009) Prevalence and definition of drooling in Parkinson’s disease, a systematic review. Journal of Neurology, 256, 1391-1396. doi:10.1007/s00415-009-5098-2
[47] Salat-Foix, D. and Suchowersky, O. (2012) The management of gastrointestinal symptoms in Parkinson’s disease. Expert Review of Neurotherapeutics, 12, 239-248. doi:10.1586/ern.11.192
[48] Lyons, K.E. and Pahwa, R. (2011) The impact and management of nonmotor symptoms of Parkinson’s disease. American Journal of Managed Care, 17, S308-S314.
[49] Quinn, N.P., Koller, W.C., Lang, A.E. and Marsden, C.D. (1986) Painful Parkinson’s disease. Lancet II, 1366-1369. doi:10.1016/S0140-6736(86)91674-0
[50] Shah, M., Deeb, J., Fernando, M., Noyce, A., Visentin, E., Findley, L.J. and Hawkes, C.H. (2009) Abnormality of taste and smell in Parkinson’s disease. Parkinsonism and Related Disorders, 15, 232-237. doi:10.1016/j.parkreldis.2008.05.008
[51] Landis, B.N. and Burkhard, P.R. (2008) Rhinorrhea and olfaction in Parkinson disease. Neurology, 71, 1041-1042. doi:10.1212/01.wnl.0000327867.15757.d0
[52] Chudler, E.H. and Dong, W.K. (1950) The role of the basal ganglia in nociception and pain. Pain, 60, 3-38. doi:10.1016/0304-3959(94)00172-B
[53] Shyu, B.C., Kititsy-Roy, J.A. and Morrow, T.J. (1992) Neurophysiological, pharmacological and behavioural evidence for medial thalamic mediation of cocaine induced dopaminergic analgesia. Brain Research, 522, 216-223. doi:10.1016/0006-8993(92)90472-L
[54] Weintraub, D., Sohr, M., Potenza, M.N., Siderowf, A.D., Stacy, M., Voon, V., Whetteckey, J., Wunderlich, G.R. and Lang, A.E. (2010) Amantadine use associated with impulse control disorders in Parkinson disease in cross-sectional study. Annals of Neurology, 68, 963-968. doi:10.1002/ana.22164
[55] Abe, K. (2006) Tiredness and fatigue. Journal of International Society of Life Information Science, 24, 60-62.
[56] Abe, K. (2001) Tiredness and fatigue. Brain, 21, 35-39.
[57] Abe, K., Takanashi, M., Yanagihara, T. and Sakoda, S. (2002) Pergolide mesilate may improve fatigue in patients with Parkinson’s disease. Behavioural Neurology, 13, 117- 121.
[58] Schrag, A., Jahanshahi, M. and Quinn, N. (2000) What contributes to quality of life in patients with Parkinson’s disease? Journal of Neurology Neurosurgery & Psychiatry, 69, 308-312. doi:10.1136/jnnp.69.3.308
[59] Martinez-Martine, P., Benito-León, J., Alonso, F., Catalán, M.J., Pondal, M., Zamarbide, I., Tobías, A., de Pedro, J. Quality of life of caregivers in Parkinson’s disease. Quality of Life Research, 14, 463-472. doi:10.1007/s11136-004-6253-y
[60] Krupp, L.B., Coyle, P.K. and Doscher, C. (1995) Fatigue therapy in multiple svlerosis—Results of a double-blind, randomized, parallel trial of amantadine, remoline, and placebo. Neurology, 45, 1956-1961. doi:10.1212/WNL.45.11.1956
[61] Pavese, N., Metta, V,. Bose, S.K., Chaudhuri, K.R. and Brooks, D.J. (2010) Fatigue in Parkinson’s disease is linked to striatal and limbic serotonergic dysfunction. Brain, 33, 3434-3443. doi:10.1093/brain/awq268
[62] Tamaki, A., Matsuo, Y. and Abe, K. (2000) Influence of Thoracoabdominal movement on pulmonary function in patients with Parkinson’s disease. Comparison with healthy subjects. Neurorehabilitation and Neural Repair, 14, 43- 47. doi:10.1177/154596830001400105
[63] Matsuo, Y., Kamata, N. and Abe, K. (2006) Thoraco-abnominal movements during deep breathing in patients with Parkinson’s disease may be reduced parallel to disease progression. Clinical Neurophysiology, 117, S185. doi:10.1016/j.clinph.2006.06.334

Copyright © 2023 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.